Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Paraoxonase-1 is a major determinant of clopidogrel efficacy

A Corrigendum to this article was published on 07 September 2011

This article has been updated

Abstract

Clinical efficacy of the antiplatelet drug clopidogrel is hampered by its variable biotransformation into the active metabolite1,2. The variability in the clinical response to clopidogrel treatment has been attributed to genetic factors, but the specific genes and mechanisms underlying clopidogrel bioactivation remain unclear. Using in vitro metabolomic profiling techniques, we identified paraoxonase-1 (PON1) as the crucial enzyme for clopidogrel bioactivation, with its common Q192R polymorphism determining the rate of active metabolite formation. We tested the clinical relevance of the PON1 Q192R genotype in a population of individuals with coronary artery disease who underwent stent implantation and received clopidogrel therapy. PON1 QQ192 homozygous individuals showed a considerably higher risk than RR192 homozygous individuals of stent thrombosis, lower PON1 plasma activity, lower plasma concentrations of active metabolite and lower platelet inhibition. Thus, we identified PON1 as a key factor for the bioactivation and clinical activity of clopidogrel. These findings have therapeutic implications and may be exploited to prospectively assess the clinical efficacy of clopidogrel.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Kinetics of clopidogrel-metabolizing enzymes.
Figure 2: Kaplan-Meier curves for individuals with coronary stent implantation and their pharmacokinetic and pharmacodynamic responses to clopidogrel.

Change history

  • 21 December 2010

     In the version of this article originally published online, the affiliations for Hans-Günther Schmalz and Dirk Taubert appeared incorrectly. Hans-Günther Schmalz is in the Department für Chemie, Universität zu Köln, Cologne, Germany, and Dirk Taubert is in the Department of Pharmacology, University Hospital of Cologne, Cologne, Germany. These errors have been corrected for the print, PDF and HTML versions of the article.

  • 07 September 2011

     In the first paragraph on page 112, the authors made a typographical error: "constitutes part the active histidine dyad" should have been "is proximate to the active histidine dyad."

References

  1. Gurbel, P.A., Antonino, M.J. & Tantry, U.S. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin. Drug Metab. Toxicol. 5, 989–1004 (2009).

    Google Scholar 

  2. Angiolillo, D.J. & Ferreiro, J.L. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev. Esp. Cardiol. 63, 60–76 (2010).

    Google Scholar 

  3. Serebruany, V.L. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. 45, 246–251 (2005).

    Google Scholar 

  4. Sofi, F. et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb. Haemost. 103, 841–848 (2010).

    Google Scholar 

  5. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J. Am. Med. Assoc. 302, 849–857 (2009).

    Google Scholar 

  6. Hulot, J.-S. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J. Am. Coll. Cardiol. 56, 134–143 (2010).

    Google Scholar 

  7. Holmes, D.R. Jr. et al. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122, 537–557 (2010).

    Google Scholar 

  8. Taubert, D. et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost. 92, 311–316 (2004).

    Google Scholar 

  9. Bouman, H.J. et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J. Thromb. Haemost. 8, 482–488 (2010).

    Google Scholar 

  10. Pereillo, J.M. et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab. Dispos. 30, 1288–1295 (2002).

    Google Scholar 

  11. Dansette, P.M., Libraire, J., Bertho, G. & Mansuy, D. Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem. Res. Toxicol. 22, 369–373 (2009).

    Google Scholar 

  12. Kazui, M. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38, 92–99 (2010).

    Google Scholar 

  13. Wheeler, J.G., Keavney, B.D., Watkins, H., Collins, R. & Danesh, J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363, 689–695 (2004).

    Google Scholar 

  14. Billecke, S. et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28, 1335–1342 (2000).

    Google Scholar 

  15. Adkins, S., Gan, K.N., Mody, M. & La Du, B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52, 598–608 (1993).

    Google Scholar 

  16. Harel, M. et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11, 412–419 (2004).

    Google Scholar 

  17. Prentice, R.L. On the design of synthetic case-control studies. Biometrics 42, 301–310 (1986).

    Google Scholar 

  18. King, S.B. III et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117, 261–295 (2008).

    Google Scholar 

  19. Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363–375 (2009).

    Google Scholar 

  20. Angiolillo, D.J. et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler. Thromb. Vasc. Biol. 26, 1895–1900 (2006).

    Google Scholar 

  21. Suh, J.W. et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174, 1715–1722 (2006).

    Google Scholar 

  22. Brandt, J.T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429–2436 (2007).

    Google Scholar 

  23. Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494–502 (2001).

    Google Scholar 

  24. Gurbel, P.A., Becker, R.C., Mann, K.G., Steinhubl, S.R. & Michelson, A.D. Platelet function monitoring in patients with coronary artery disease. J. Am. Coll. Cardiol. 50, 1822–1834 (2007).

    Google Scholar 

  25. Sibbing, D. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53, 849–856 (2009).

    Google Scholar 

  26. Clarke, T.A. & Waskell, L.A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. 31, 53–59 (2003).

    Google Scholar 

  27. Correia, M.A. & Ortiz de Montellano, P.R. Inhibition of cytochrome P450 enzymes. in Cytochrome P450: Structure, Mechanism, and Biochemistry (ed. Ortiz de Montellano, P.R.) 253 (Kluwer Academic/Plenum Publishers, New York, 2005).

  28. Kosaka, T., Yamaguchi, M., Motomura, T. & Mizuno, K. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin. Chim. Acta 359, 156–162 (2005).

    Google Scholar 

  29. Perla-Kaján, J. & Jakubowski, H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J. 24, 931–936 (2010).

    Google Scholar 

  30. Bertrand-Thiébault, C. et al. Genetic polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation. Ann. Hum. Genet. 72, 178–183 (2008).

    Google Scholar 

  31. Bhattacharyya, T. et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. J. Am. Med. Assoc. 299, 1265–1276 (2008).

    Google Scholar 

  32. Rainwater, D.L. et al. Determinants of variation in human serum paraoxonase activity. Heredity 102, 147–154 (2009).

    Google Scholar 

  33. Barlow, W.E., Ichikawa, L., Rosner, D. & Izumi, S. Analysis of case-cohort designs. J. Clin. Epidemiol. 52, 1165–1172 (1999).

    Google Scholar 

Download references

Acknowledgements

We are grateful to all subjects who participated in the study. We thank numerous unnamed staff of our institutions for their efforts in subject recruitment, clinical, laboratory and experimental assessments.

Author information

Authors and Affiliations

Authors

Contributions

J.W.v.W. and D.T. conceived the project. E.S., J.M.t.B. and D.T. supervised the project. H.J.B., J.W.v.W., J.V., C.M.H., C.H., C.W., H.-G.S. and D.T. conducted or directed bioanalytics of clopidogrel and its metabolites, metabolomic profiling, blood collection and sample preparation, aggregometry, genotyping and PON1 phenotyping. H.J.B., E.S., J.W.v.W., C.M.H., J.M.t.B. and D.T. conducted or directed recruitment of subjects, disease assessment and follow-up assessments. H.J.B., J.W.v.W. and D.T. did the computational and statistical data analyses. H.J.B. and D.T. wrote the manuscript.

Corresponding author

Correspondence to Dirk Taubert.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Tables 1–10, Supplementary Figures 1–9 and Supplementary Methods (PDF 589 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bouman, H., Schömig, E., van Werkum, J. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17, 110–116 (2011). https://doi.org/10.1038/nm.2281

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2281

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing